• Educational resources
  • Events
  • Expert Panel
  • Learning Hub
    Learning Hub
    • Bullous Pemphigoid Learning Hub
    • Chronic Spontaneous Urticaria Learning Hub
    • COPD Learning Hub
    • Rhinology Learning Hub
    • Type 2 Asthma Learning Hub
    • Prurigo Nodularis Learning Hub
    • Atopic Dermatitis Learning Hub
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: MalaysiaChange country/region
Dermatology

Identification and Management of AD Uncontrolled With Topical Therapies in Children

In this expert interview video focusing on topics from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang discusses how to identify pediatric patients with AD uncontrolled with topical therapies, considerations for the next step in care for these patients, and the potential benefits of early intervention with systemic treatment
Perla Lansang
MD
Perla Lansang
3 minutes

Related resources

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

5 min
videoanimation
What is Early Intervention in AD?

What is Early Intervention in AD?

3 min
expert video
Disease Modification in AD

Disease Modification in AD

3 min
expert video
Systemic Inflammation in AD – Beyond the Skin

Systemic Inflammation in AD – Beyond the Skin

4 min
expert video
Dysbiosis, Skin Infections, and Itch

Dysbiosis, Skin Infections, and Itch

3 min
expert video
Skin Barrier Dysfunction in AD

Skin Barrier Dysfunction in AD

4 min
expert video
Early Intervention and the Potential for Disease Modification in Children With AD

Early Intervention and the Potential for Disease Modification in Children With AD

15 min
expert video
Emerging Data on Advanced Systemic Treatments for Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD

15 min
expert video
Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

15 min
expert video
Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

43 min
expert video
Explore the clinical presentations of bullous pemphigoid (BP), the steps for diagnosis, and the burden of disease.

Bullous Pemphigoid (BP): Don't Miss the Diagnosis

10 min
Infographic
Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

2 min
expert video
Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

2 min
expert video
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

5 min
expert video
Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

5 min
expert video
A brief overview of the pathophysiology of PN

A brief overview of the pathophysiology of PN

5 min
expert video
Most Burdensome Symptoms Rated by PN Patients

Most Burdensome Symptoms Rated by PN Patients

1 min
expert video
Current systemic therapies have been shown to induce remission in a subset of AD patients

Current systemic therapies have been shown to induce remission in a subset of AD patients

5 min
expert video
Can advanced systemic therapies modify pathomechanisms in AD?

Can advanced systemic therapies modify pathomechanisms in AD?

5 min
expert video
Diagnosis of Bullous Pemphigoid Interactive Patient Case

Diagnosis of Bullous Pemphigoid Interactive Patient Case

10 min
interactivity
Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD

20 min
expert video
ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

23 min
Podcast
ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

20 min
Podcast
ADVENT On Air | Exploring PN as a Distinct and Unique Disease

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

20 min
Podcast
Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

Factors Contributing to Diagnostic Delays in Bullous Pemphigoid

2 min
expert video
Pathophysiology of Blister Formation in Bullous Pemphigoid

Pathophysiology of Blister Formation in Bullous Pemphigoid

2 min
expert video
What do we mean by disease control in AD?

What do we mean by disease control in AD?

3 min
expert video
Barrier disruption in AD and the development of environmental and food allergies

Barrier disruption in AD and the development of environmental and food allergies

5 min
expert video
ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

20 min
Podcast
Etiology and Diagnosis of Bullous Pemphigoid

Etiology and Diagnosis of Bullous Pemphigoid

2 min
expert video
What Could Remission Mean in AD?

What Could Remission Mean in AD?

1 min
expert video
The Risks of Associated Systemic and Atopic Comorbidities with AD

The Risks of Associated Systemic and Atopic Comorbidities with AD

5 min
expert video
Factors Associated With Development of Atopic Comorbidities in AD

Factors Associated With Development of Atopic Comorbidities in AD

1 min
expert video
Can Early Intervention Shape the Course of Atopic Dermatitis?

Can Early Intervention Shape the Course of Atopic Dermatitis?

8 min
expert video
Association of Younger Age of Onset With Persistence of AD

Association of Younger Age of Onset With Persistence of AD

1 min
expert video
CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

5 min
Infographic
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

6 min
videoanimation
Explore the Global Burden of Pediatric AD (PEDISTAD)

Explore the Global Burden of Pediatric AD (PEDISTAD)

15 min
interactivity
Type 2 Inflammation in AD Manifestations in Skin and Body

Type 2 Inflammation in AD Manifestations in Skin and Body

6 min
expert video
Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

Can targeting IL-4 and IL-13 have an effect on relieving the burden of atopic and non-atopic comorbidities in AD?

5 min
expert video
Can early intervention modify the course of AD?

Can early intervention modify the course of AD?

5 min
expert video
Impact of Advanced Systemic Therapies on Disease Control in AD

Impact of Advanced Systemic Therapies on Disease Control in AD

6 min
expert video
Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

Normalizing Skin Barrier by Inhibiting IL-4 & IL-13, or IL-13 Alone

5 min
expert video
Guideline-Based Diagnosis of Atopic Dermatitis

Guideline-Based Diagnosis of Atopic Dermatitis

15 min
interactivity
Early Intervention and Disease Modification in AD: Can We Change the Course of the Disease?

Early Intervention and Disease Modification in AD: Can We Change the Course of the Disease?

45 min
expert video
Type 2 Inflammation Within Skin Tissue in AD

Type 2 Inflammation Within Skin Tissue in AD

4 min
expert video
IL-4 Contributes to Systemic Type 2 Inflammation in AD

IL-4 Contributes to Systemic Type 2 Inflammation in AD

4 min
expert video
Diving Below the Surface of AD: The Role of Type 2 Inflammation

Diving Below the Surface of AD: The Role of Type 2 Inflammation

10 min
expert video
Considerations for Disease Modification in AD

Considerations for Disease Modification in AD

3 min
expert video
The Role of Type 2 Inflammation in Moderate-to-Severe AD

The Role of Type 2 Inflammation in Moderate-to-Severe AD

4 min
expert video

Learning objectives

  • Review the characteristics of pediatric patients with AD uncontrolled with topical therapies and the key considerations for the next step in care for these patients
Tags
symposium
MAT-GLB-2407632 - 2.0 -02/2025

About this expert

Dermatology

Perla Lansang

MD

The Hospital for Sick Children Toronto, Canada

See author’s profile
Perla Lansang